TuHURA Biosciences to Showcase Clinical Trial Results at ASCO 2024

TuHURA Biosciences, Inc., a company progressing to Phase 3 and specializing in immune-oncology, announced its upcoming presentation at the ASCO Annual Meeting in Chicago from May 31 to June 4, 2024. The poster presentation will focus on the Phase 1b trial results of their IFx-2.0 vaccine, targeting resistant Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC). Dr. Andrew Brohl from the Moffitt Cancer Center will present on June 1.

In a significant development, TuHURA also disclosed a definitive all-stock merger with Kintara Therapeutics. This agreement includes a substantial $31 million financing to help advance a diversified late-stage oncology pipeline. The merged entity will continue under the name TuHURA Biosciences and will be listed on the Nasdaq Capital Market under the ticker "HURA". Completion of this merger is subject to customary closing conditions and is anticipated in the third quarter of 2024.